Question 1

What is DaVita's P/E ratio?

Accepted Answer

DaVita (DVA) P/E ratio is 20.5× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for DaVita?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For DaVita specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is DaVita's P/E ratio high or low?

Accepted Answer

DaVita's P/E ratio of 20.5× is above its own 5-year average of 13.5× and below the sector median of 24.2×. That places the current reading at the 98th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is DaVita's historical P/E ratio range?

Accepted Answer

In the available daily series, DaVita (DVA) P/E ratio has ranged from a low of 8.0× in 2003 to a high of 70.3× in 2019. The 5-year average is 13.5× and the 5-year median is 13.2×.

Question 7

What was DaVita's P/E ratio in 2025?

Accepted Answer

DaVita (DVA) P/E ratio at the end of 2025 was 13.1×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does DaVita's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$9.78B	$747M	13.1×	+0.1×	Dec 31, 2025
2024	$12.2B	$936M	13.0×	-0.7×	Dec 31, 2024
2023	$9.47B	$692M	13.7×	+1.7×	Dec 31, 2023
2022	$6.73B	$560M	12.0×	+0.3×	Dec 31, 2022
2021	$11.5B	$978M	11.7×	-5.2×	Dec 31, 2021
2020	$13.1B	$774M	16.9×	+5.0×	Dec 31, 2020
2019	$9.71B	$811M	12.0×	-41.6×	Dec 31, 2019
2018	$8.54B	$159M	53.6×	+33.7×	Dec 31, 2018
2017	$13.2B	$664M	19.8×	+5.7×	Dec 31, 2017
2016	$12.5B	$880M	14.2×	-39.8×	Dec 31, 2016
2015	$14.6B	$270M	54.0×	+31.6×	Dec 31, 2015
2014	$16.1B	$723M	22.3×	+1.2×	Dec 31, 2014
2013	$13.3B	$633M	21.1×	+0.2×	Dec 31, 2013
2012	$11.2B	$536M	20.8×	+6.0×	Dec 31, 2012
2011	$7.09B	$478M	14.8×	-1.7×	Dec 31, 2011
2010	$6.69B	$406M	16.5×	+2.2×	Dec 31, 2010
2009	$6.03B	$423M	14.3×	+0.5×	Dec 31, 2009
2008	$5.15B	$374M	13.8×	-2.0×	Dec 31, 2008
2007	$6.02B	$382M	15.8×	-4.7×	Dec 31, 2007
2006	$5.93B	$290M	20.5×	-2.1×	Dec 31, 2006
2005	$5.16B	$229M	22.6×	+5.1×	Dec 31, 2005
2004	$3.87B	$222M	17.4×	+3.2×	Dec 31, 2004
2003	$2.51B	$176M	14.3×	+4.9×	Dec 31, 2003
2002	$1.48B	$157M	9.4×	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for DaVita (DVA) 2002-2026

P/E Ratio daily chart for DaVita (DVA)

Historical P/E Ratio for DaVita (DVA) from 2002 to 2025

About P/E Ratio at DaVita (DVA)

DaVita P/E Ratio by Year

DaVita P/E Ratio 2025: 13.1×

DaVita P/E Ratio 2024: 13.0×

DaVita P/E Ratio 2023: 13.7×

DaVita P/E Ratio 2022: 12.0×

DaVita P/E Ratio 2021: 11.7×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

DaVita (DVA) Key Financials